Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma

Ayman Qasrawi, Ranjana Arora, Reshma Ramlal, Reinhold Munker, Gerhard C. Hildebrandt

Research output: Contribution to journalLetterpeer-review

5 Scopus citations
Original languageEnglish
Pages (from-to)E89-E91
JournalAmerican Journal of Hematology
Volume95
Issue number4
DOIs
StatePublished - Apr 2020

Bibliographical note

Funding Information:
GCH reports equity ownership from Sangamo Bioscience, Celgene/Juno, Kite Pharmaceuticals, Novartis, Insys Therapeutics, AbbVie, GW Pharmaceuticals, Cardinal Health, Immunomedics, Endocyte, Clovis Oncology, Cellectis, Aetna, CVS Health, Celgene, Bluebird Bio, Bristol‐Myers Squibb/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, and Jazz Pharmaceuticals, consultancy from Pfizer, Kite Pharmaceuticals, Incyte, and Jazz Pharmaceuticals, research funding from Takeda, Jazz Pharmaceuticals, and Pharmacyclin, travel, accommodations, or expenses from Kite Pharmaceuticals, Incyte, Pfizer, Falk Foundation, Jazz Pharmaceuticals, and Astellas.

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this